Novel fluoronucleoside analog NCC inhibits lamivudine-resistant hepatitis B virus in a hepatocyte model.
PMID: 30586543
2018
The Brazilian journal of infectious diseases
1Abstract: We generated a stable cell line encoding the major pattern of lamivudine-resistant mutations rtL180M/M204V and designated it ""HepG2.RL1""."
High Prevalence of HBV Lamivudine-Resistant Mutations in HBV/HIV Co-Infected Patients on Antiretroviral Therapy in the Area with the Highest Prevalence of HIV/HBV Co-Infection in China.
Abstract: HBV harboring the rtA181C substitution without LVDr substitutions rtL180M+rtM204V remained susceptible to inhibition by ETV, adefovir, and tenofovir, although cross-resistance to LVD and telbivudine was observed.
Abstract: One LVD-experienced patient-derived HBV RT harboring LVDr substitutions rtL180M+rtM204V with rtA181C displayed reduced ETV susceptibility (122-fold greater than wild-type HBV) and remained susceptible to adefovir and tenofovir.
Abstract: Previous studies revealed that ETV-resistant (ETVr) HBV DNA re
Genetic variability in coding regions of the surface antigen and reverse transcriptase domain of hepatitis B virus polymerase, Colombia, 2002-2014
Abstract: The L180M and M204V resistance mutations were simultaneously identified in one sample, while the I169L resistance mutation was identified in another one.
A systematic review of hepatitis B virus (HBV) drug and vaccine escape mutations in Africa: A call for urgent action.
Abstract: We also identified the suite of mutations rtM204V/I + rtL180M + rtV173L, that has been associated with vaccine escape, in over 1/3 of cohorts.
Introduction: Virological breakthrough on TDF therapy has been reported in two patients harbouring rtS78T/sC69 mutations, and in another patient with multi-site polymerase mutations; rtL80M, rtL180M, rtM204V/I, rt PMID: 30075160
2018
Virus research
Abstract: Sequencing reverse transcriptase region of HBV revealed that the patient developed lamivudine-resistant mutations (rtV173 L, rtL180 M, and rtM204 V) 36 months after the start of lamivudine therapy, and lamivudine-resistant mutants reversed to wild-type after the treatment was stopped for 8 months.
Immune-escape mutations and stop-codons in HBsAg develop in a large proportion of patients with chronic HBV infection exposed to anti-HBV drugs in Europe.
Result: The only primary drug-resistance mutations detected were rtM204I (0.4%, 1/245) and rtN236T (0.4%, 1/245), while the only secondary mutations detected were rtL180M and rtV173L, each present in 0.4% of patients.
[Monitoring by high-sensitivity HBV DNA assay during treatment in chronic hepatitis B e antigen negative patients].
Abstract: New mutation sites such as G1915A / C, L180M, M204V, V207I / L, T184A and V173L were detected, Low resistance rate (25%).
Naturally occurring hepatitis B virus reverse transcriptase mutations related to potential antiviral drug resistance and liver disease progression.
PMID: 29713126
2018
World journal of gastroenterology
Method: Also, a recent study using direct sequencing of samples from 131 treatment-naive patients infected with genotype C2 reported an overall rate of 12.98% for primary (rtT184A/C/F and rtM204I/V) or compensatory (rtL80I and rtL180M) mutations.
Method: Another study of 325 genotype D infected treatment-naive patients using direct PCR sequencing reported overall incidence of 15.69% for primary and secondary drug resistance mutations, including L80V/I, L180M, M204I/V, and S213T/N.|m
Table: L180M
Trends in hepatitis B virus resistance to nucleoside/nucleotide analogues in North China from 2009-2016: A retrospective study.
PMID: 29654894
2018
International journal of antimicrobial agents
Abstract: Despite >50% of M204I/V+-L180M among all HBV resistance cases annually and extensive exposure of patients to lamivudine (LAM), telbivudine (LdT) and adefovir dipivoxil (ADV), ETV resistance also showed a dramatically increased incidence, which rose to 17.1% in 2016.
HBV mutation literature information.
PMID: 
2018
The Brazilian journal of infectious diseases
Browser Board
Co-occurred Entities
Filtrator
ViMRT